- Conditions
- Influenza, Human
- Interventions
- FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 833 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 8
- States / cities
- Stockbridge, Georgia • Meridian, Idaho • Cary, North Carolina + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 25
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- COVID-19 Vaccines
- Interventions
- BNT162b2 Vaccine, Tdap Vaccine
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Walnut Creek, California • Miami Lakes, Florida • Honolulu, Hawaii + 2 more
- Conditions
- Influenza
- Interventions
- Standard IIV4, Recombinant, Cell-culture
- Biological
- Lead sponsor
- Marshfield Clinic Research Foundation
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Marshfield, Wisconsin
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Interventions
- Influenza Virus Vaccine USP Trivalent Types A and B
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 4,292 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 46
- States / cities
- Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 40 more
- Conditions
- Influenza
- Interventions
- Flublok, Flucelvax, Fluarix, Fluzone, Fluzone High-Dose
- Biological
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 944 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Temple, Texas
- Conditions
- Urinary Tract Infections
- Interventions
- Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo
- Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 448 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Lenexa, Kansas • Secaucus, New Jersey • Rochester, New York + 3 more
- Conditions
- Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction, Congestive Heart Failure, Stroke
- Interventions
- Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)
- Biological
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 2,776,278 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Pneumococcal Infection
- Interventions
- V116, Placebo, PCV15, PPSV23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 518 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 8
- States / cities
- Mesa, Arizona • Hialeah, Florida • West Palm Beach, Florida + 5 more
- Conditions
- Influenza
- Interventions
- Investigational H9N2 vaccine GSK2654911A, Investigational H9N2 vaccine GSK2654909A, Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 422 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Miami, Florida • Edison, New Jersey • Austin, Texas
- Conditions
- Influenza
- Interventions
- Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation, Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 3,360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 38
- States / cities
- Hoover, Alabama • Huntsville, Alabama • Chandler, Arizona + 32 more
- Conditions
- Healthy
- Interventions
- EMSAM (Selegiline Transdermal System) 6mg/24Hr, EMSAM (Selegiline Transdermal System) 9mg/24Hr, EMSAM (Selegiline Transdermal System) 12mg/24hr
- Drug
- Lead sponsor
- Somerset Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • St. Petersburg, Florida
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections, Influenza
- Interventions
- Quadrivalent VLP Vaccine, Placebo
- Biological
- Lead sponsor
- Medicago
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 10,160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 29
- States / cities
- Mobile, Alabama • Anaheim, California • Milford, Connecticut + 23 more
- Conditions
- Influenza
- Interventions
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Mesa, Arizona
- Conditions
- Influenza
- Interventions
- CAIV-T
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000
- U.S. locations
- 1
- States / cities
- Stamford, Connecticut
- Conditions
- Patients Who Consented to Undergo Laparoscopic Gastric Banding Surgery for Weight Loss and Consent to Participate in This studyBMI ≥35 kg/m2, Confirmed Type 2 Diabetes Treated With Oral Agents and/or Only Diet Therapy, Age 18-64 Years
- Interventions
- Omentectomy, No intervention
- Procedure · Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Influenza
- Interventions
- GSK A/turkey H5N1 Influenza vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 469 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more
- Conditions
- Diabetes
- Interventions
- Education
- Behavioral
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Interventions
- 15 µg/strain of Quadrivalent VLP Vaccine, 30 µg/strain of Quadrivalent VLP Vaccine, 15 µg/strain of the licensed quadrivalent vaccine
- Biological
- Lead sponsor
- Medicago
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • South Miami, Florida • Endwell, New York
- Conditions
- Influenza
- Interventions
- Investigational H7N9 vaccine GSK3206641A, Investigational H7N9 vaccine GSK3206640A, Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 424 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Jacksonville, Florida • Stockbridge, Georgia • Boise, Idaho + 2 more
- Conditions
- Influenza
- Interventions
- Cell-Derived Trivalent Subunit Influenza Vaccine, Placebo
- Biological
- Lead sponsor
- Abbott Biologicals
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 1,270 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 15
- States / cities
- Jacksonville, Florida • Pembroke Pines, Florida • South Miami, Florida + 12 more
- Conditions
- Influenza
- Interventions
- Flucelvax® (ccIIV3), Flublok® (RIV3)
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 606 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Atlanta, Georgia + 3 more
- Conditions
- Influenza, Human
- Interventions
- Fluzone Quadrivalent, Flublok Quadrivalent
- Biological
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 3,988 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Tallahassee, Florida • Houston, Texas + 1 more
- Conditions
- Pneumococcal Vaccines
- Interventions
- 24 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 835 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 13
- States / cities
- Hollywood, Florida • Sunrise, Florida • Savannah, Georgia + 10 more
- Conditions
- Influenza
- Interventions
- Influenza Virus Vaccine USP Trivalent Types A and B
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 1,250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 44
- States / cities
- Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 38 more